Efficacy Of Rhokinase Inhibitors New Class Of AntiPulmonary Arterial Hypertention(PAH) Drugs Encapsulated In LongActing Inhalable Particles And PatientCompliant Therapy For The LongTerm Treatment Of PAH in Saudi population

Pharmacology, Toxicology and Pharmaceutical Science

1. Chronic Obstructive Lung Disease 22%
2. Diseases 5%
3. Fasudil 14%
4. Iloprost 18%
5. Microsphere 7%
6. Nitric Oxide 9%
7. Prevalence 5%
8. Prostacyclin 11%
9. Prostacyclin Derivative 6%
10. Pulmonary Hypertension 100%
11. Rho Kinase 5%
12. Treprostinil 7%